Complete pathologic clearance with vismodegib in advanced basal cell carcinoma of the scalp with cranial invasion

被引:0
|
作者
Dodson, Joseph [1 ]
Kelm, Ryan [2 ]
Cavanaugh, Kevin [2 ]
机构
[1] Rush Univ, Med Ctr, Chicago, IL USA
[2] Rush Univ, Dept Dermatol, Med Ctr, Chicago, IL USA
来源
JPRAS OPEN | 2022年 / 34卷
关键词
Neoadjuvant; Advanced basal cell carcinoma; Cranium; Immunocompromised; Vismodegib; Hedgehog Pathway Inhibitor; PATHOGENESIS;
D O I
10.1016/j.jpra.2022.09.001
中图分类号
R61 [外科手术学];
学科分类号
摘要
The management of advanced basal cell carcinoma (BCC) can be challenging and often involves a multi-disciplinary approach with dermatologists, plastic surgeons, and oncologists. Standard therapy for advanced BCCs has historically involved prompt excision and radiation; however, in recent years, management strategies utilizing hedgehog pathway inhibitors as neoadjuvant therapy have gained popularity. While controversy regarding management recommendations still exists, we present a case of advanced BCC with cranial involvement in an immunocompromised patient where the use of neoadjuvant vismodegib led to a favorable outcome and, surprisingly, complete the pathologic clearance of the tumor. (c) 2022 The Authors. Published by Elsevier Ltd on behalf of British Association of Plastic, Reconstructive and Aesthetic Surgeons.
引用
收藏
页码:168 / 172
页数:5
相关论文
共 50 条
  • [1] Pathologic complete response with radiation and vismodegib in a patient with advanced basal cell carcinoma: A case report
    Amini, Arya
    Freeman, Morganna
    Melstrom, Laleh
    Margolin, Kim A.
    Parekh, Vishwas
    Abdulla, Farah R.
    Modi, Badri
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (03)
  • [2] Complete remission of advanced, locally invasive basal cell carcinoma with vismodegib
    Glen, P.
    Farrugia, D.
    Farrier, J.
    INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2020, 49 (09) : 1149 - 1152
  • [3] Vismodegib: A Review in Advanced Basal Cell Carcinoma
    Frampton, James E.
    Basset-Seguin, Nicole
    DRUGS, 2018, 78 (11) : 1145 - 1156
  • [4] VISMODEGIB IN BASAL CELL CARCINOMA
    Amaria, R. N.
    Bowles, D. W.
    Lewis, K. D.
    Jimeno, A.
    DRUGS OF TODAY, 2012, 48 (07) : 459 - 467
  • [5] Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia
    Mesti, Tanja
    Sever, Masa
    Ocvirk, Janja
    DERMATOLOGY, 2023, 239 (01) : 158 - 164
  • [6] Vismodegib and orbital excision for treating locally advanced basal cell carcinoma
    Hogarty, Daniel T.
    Dewhurst, Nicholas G.
    Burt, Benjamin
    INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2018, 11 : 177 - 179
  • [7] Vismodegib: The first drug approved for advanced and metastatic basal cell carcinoma
    Dubey, A. K.
    Dubey, S.
    Handu, S. S.
    Qazi, M. A.
    JOURNAL OF POSTGRADUATE MEDICINE, 2013, 59 (01) : 48 - 50
  • [8] Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma
    Lavasidis, Georgios
    Tzamalis, Argyrios
    Tsinopoulos, Ioannis
    Ziakas, Nikolaos
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 39
  • [9] Role of Vismodegib in the Management of Advanced Periocular Basal Cell Carcinoma
    Cox, Kyle F.
    Margo, Curtis E.
    CANCER CONTROL, 2016, 23 (02) : 133 - 139
  • [10] Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma
    Pollom, Erqi L.
    Bui, Timothy T.
    Chang, Anne Lynn S.
    Colevas, A. Dimitrios
    Hara, Wendy Y.
    JAMA DERMATOLOGY, 2015, 151 (09) : 998 - 1001